Slate Medicines Launches with $130 Million Series A Financing to Advance Anti-PACAP Therapies for the Prevention of Migraine and Other Headache Disorders
Lead program, SLTE-1009, licensed from DartsBio Pharmaceuticals (Guangdong), Ltd, is a potentially best-in-class anti-PACAP monoclonal antibody with half-life extension to enable subcutaneous dosing and is on track to initiate Phase 1 clinical trials in mid-2026…